The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

BSG005 Drug Profile


Biosergen’s antifungal drug candidate, BSG005, is the fruit of a groundbreaking effort over the last two decades by SINTEF (one of Europe’s largest independent research organisations) and the NTNU (Norge’s Teknisk-Videnskabelige Universitet in Trondheim, Norway) to develop an improved version of Nystatin, a naturally occurring fungicidal chemical in the bacterial strain Streptomyces noursei. Work that to date has been published in more than 20 international peer reviewed scientific publications.

 

 

 

 

BSG005 has been shown to have a fungicidal spectrum of action against all fungus strains responsible for invasive fungal disease mentioned above, not least against Azole and Echinocandin resistant Aspergillus and Candida strains. At similar dose levels, the drug demonstrates solid in vivo potency advantages over new liposomal formulations of Amphotericin B, the current standard of care for patients not responding to Azole and Echinocandin treatment, of 3 - 4 times higher potency. BSG005 has no kidney toxicity, the main shortcoming and limitation of all other polyenes.  

The Company is not aware of any other antifungal on the market or in development with a similar profile.